FDA OKs Kcentra as antidote to warfarin

04/30/2013 | Los Angeles Times (tiered subscription model)

The FDA has approved the prothrombin complex concentrate Kcentra as a reversal agent for the anticoagulant warfarin. Health care providers will not need to match Kcentra with a patient's blood type, so it can be used faster than plasma to reverse the effects of warfarin. It cannot be used to reverse the effects of newer anticoagulants dabigatran and rivaroxaban.

View Full Article in:

Los Angeles Times (tiered subscription model)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Project Manager RA - 15000003MD
Abbott
Santa Clara, CA
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
CT
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC